Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    Collage VEP Ross White

      Dr David Ross     Dr Deborah White




     Session 3: Future directions for CML

    • TFR trial update 
      (Dr David Ross)
    • Biomarkers and response prediction 
      in CML
      (Dr Deborah White)



    David Ross



    TFR trial update
    Dr David Ross- SA Pathology, Universities of Adelaide and South Australia

    • Deep molecular response and treatment-free remission
    • Imatinib TFR findings
    • TFR experience with nilotinib and dasatinib
    • Maximising eligibility for TFR
    • Future and ongoing research questions
    • Conclusions and practical recommendations


    Deborah White


    Biomarkers and response prediction in CML
    Dr Deborah White - SAHRMI, University of Adelaide

    • Chemokines, cytokines and growth factors
    • KIR genotypes
    • CIP2A
    • Drug transporters
    • Genomics
    • Drug monitoring and compliance